INTRODUCTION {#s1}
============

A steady decline of gastric carcinoma (GC) incidence has been observed worldwide, primarily as a result of a reduction in distal GC \[[@R1]\]. However, GC is the fourth most common malignancy and is a relatively higher incidence in Eastern Asian (e.g. China, Korea and Japan). Esophagogastric junction adenocarcinoma (EGJA) is one of the most rapidly increasing malignancies in North America and Europe and is thought to have different etiology compared to distal GC \[[@R2]\]. Recently, the increasing incidence of EGJA was also identified in Eastern Asian \[[@R3], [@R4]\]. EGJA is a highly fatal form of malignancies and is a major public health problem in China. The potential risk factors contributing to EGJA are foods preserved by salting, smoking and obesity *et al*. In addition, it is reported that individual\'s genetic background also plays an important role in pathogenesis of EGJA. Although a number of studies have focused on the etiology of EGJA, it is not well understood. Of late, some studies reported the immune system might be implicated in the etiology of EGJA \[[@R5], [@R6]\].

*Programmed cell death 1* (*PD-1*) gene was found by Ishida Y in 1992 \[[@R7]\]. It is classified as a member of the immunoglobulin superfamily (IgSF). As other inhibitory costimulatory molecules, PD-1 is expressed on many immunocytes, such as T cells, exhausted T cells, regulatory T cells (Treg), activated monocytes, B cells, natural killer (NK) cells, dendritic cells (DCs) and natural killer T (NKT) cells \[[@R8], [@R9]\]. PD-1 protein, a transmembrane glycoprotein, consists of an intracellular domain and an extracellular immunoglobulin V domain. PD-1 protein binds two ligands, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2). Under common physiological conditions, PD-1 interacts with PD-L1 and PD-L2, and then regulates a immune checkpoint. PD-1 may play a very important role in reducing the function of immune system by inhibiting T-cells and up-regulating Treg \[[@R10]\]. Finally, it decreases autoimmunity and results in self-tolerance.

Most recent studies reported several polymorphisms in *PD-1* gene may be associated with susceptibility to some human autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, and ankylosing spondylitis *et al*.) \[[@R11]--[@R16]\]. Interestingly, accumulating evidences showed that *PD-1* single nucleotide polymorphisms (SNPs) were also correlated with susceptibility to human malignancy (e.g., thyroid cancer, breast cancer, cervical cancer, non-small cell lung cancer and gastric cancer *et al*.) \[[@R17]--[@R21]\]. The immune response may be differ greatly among individual tumor hosts, and the potential mechanisms remain unknown. Genetic variations can influence the function of genes and alter the disease phenotypes. Thus, the effect of such functional polymorphisms in immune response genes on cancer risk has attracted our interest. Exploring the relationship of *PD-1* SNPs with EGJA risk may be beneficial for providing prevention and personalized diagnosis. Here, we selected *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms and designed a hospital-based case-control study to determine the potential relationship between these functional SNPs in *PD-1* gene and EGJA risk.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

The demographics (age and sex) and major risk factors (smoking and drinking status) of participants are summarized in Table [1](#T1){ref-type="table"}. The mean ± SD of age was not significant in the EGJA patients compared with non-cancer controls (*P* \> 0.05). Our study was well-matched by age and gender. Significant difference was observed on smoking status and alcohol consumption between the EGJA patients and the controls (*P* \< 0.001). For *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms, the success rate of genotyping was more than 99%, respectively (Table [2](#T2){ref-type="table"}). The minor allele frequency (MAF) in our controls was similar to the data of Chinese population. The distribution of genotype frequencies in controls accorded with Hardy--Weinberg equilibrium (HWE) (Table [2](#T2){ref-type="table"}).

###### Distribution of selected demographic variables and risk factors in EGJA cases and controls

  Variable         Overall Cases (*n* = 1,063)   Overall Controls (*n* = 1,677)   *P*^a^                   
  ---------------- ----------------------------- -------------------------------- ---------------- ------- ----------
  Age (years)      64.19 (±8.63)                                                  63.91 (±10.22)           0.451
  Age (years)                                                                                              0.165
   \< 64           494                           46.47                            825              49.19   
   ≥64             569                           53.53                            852              50.81   
  Sex                                                                                                      0.909
   Male            759                           71.40                            1194             71.20   
   Female          304                           28.60                            483              28.80   
  Smoking status                                                                                           \< 0.001
   Never           773                           72.72                            1323             78.89   
   Ever            290                           27.28                            354              21.11   
  Alcohol use                                                                                              \< 0.001
   Never           908                           85.42                            1507             89.86   
   Ever            155                           14.58                            170              10.14   

^a^ Two-sided *χ*^2^ test and Student *t* test.

###### Primary information for *PD-1* polymorphisms (*PD-1* rs10204525 T\>C, rs36084323 T\>C, rs7421861 A\>G and rs2227982 A\>G)

  Genotyped polymorphisms                     rs10204525 T\>C (PD1.6)   rs36084323 T\>C (PD1.1)   rs7421861 A\>G (PD1.7)   rs2227982 A\>G (PD1.9)
  ------------------------------------------- ------------------------- ------------------------- ------------------------ ------------------------
  Chr                                         2                         2                         2                        2
  Position_37                                 242792321                 242801596                 242795350                242793433
  Region                                      3′UTR                     Promoter                  Intron 1                 Exon 5
  MAF^a^ for Chinese in database              0.302                     0.490                     0.165                    0.488
  MAF in our controls (n = 1,677)             0.280                     0.496                     0.168                    0.492
  *P* value for HWE^b^ test in our controls   0.888                     0.071                     0.232                    0.309
  \% Genotyping value                         99.01                     99.09                     99.09                    99.09

^a^MAF: minor allele frequency;

^b^HWE: Hardy--Weinberg equilibrium.

Association of PD-1 rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms with EGJA {#s2_2}
---------------------------------------------------------------------------------------------------------------

The genotype distributions of *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms are summarized in Table [3](#T3){ref-type="table"}. The frequencies of *PD-1* rs2227982 AA, AG, and GG genotypes were 26.13%, 52.74% and 21.13% in 1,063 EGJA patients and 26.40%, 48.75%, and 24.85% in 1,677 controls, respectively. When compared with the frequency of *PD-1* rs2227982 AA genotype, a difference in the frequency of *PD-1* rs2227982 GG genotype was found between the EGJA patients and the controls (crude OR = 0.80, 95% CI: 0.64--1.00, *P* = 0.047). When compared with the frequency of *PD-1* rs2227982 AA/AG genotype, there was a difference in the frequency of *PD-1* rs2227982 GG genotype between EGJA patients and the controls (crude OR = 0.81, 95% CI: 0.67--0.98, *P* = 0.026). Adjustment for age, sex, smoking and drinking, there was also difference in recessive genetic model (GG vs. AA/AG: adjusted OR, 0.81; 95% CI, 0.67--0.97; *P* = 0.024; Table [4](#T4){ref-type="table"}).

###### The frequencies of *PD-1* rs10204525 T\>C, rs36084323 T\>C, rs7421861 A\>G and rs2227982 A\>G polymorphisms in esophagogastric junction adenocarcinoma patients and controls

  Genotype          Overall EGJA case (*n* = 1,063)   Overall Controls (*n* = 1,677)           
  ----------------- --------------------------------- -------------------------------- ------- -------
  rs36084323 T\>C                                                                              
  TT                282                               27.09                            444     26.52
  TC                521                               50.05                            800     47.79
  CC                238                               22.86                            430     25.69
  CT+CC             759                               72.91                            1,230   73.48
  TT+CT             803                               77.14                            1,244   74.31
  C allele          997                               47.89                            1,660   49.58
  rs10204525 T\>C                                                                              
  TT                544                               52.36                            870     51.97
  TC                397                               38.21                            672     40.14
  CC                98                                9.43                             132     7.89
  TC+CC             495                               47.64                            804     48.03
  TT+TC             941                               90.57                            1,542   92.11
  C allele          593                               28.54                            936     27.96
  rs7421861 A\>G                                                                               
  AA                642                               61.67                            1,166   69.65
  AG                358                               34.39                            454     27.12
  GG                41                                3.94                             54      3.23
  AG+GG             399                               38.33                            508     30.35
  AA+AG             1,000                             96.06                            1,620   96.77
  G allele          440                               21.13                            562     16.79
  rs2227982 A\>G                                                                               
  AA                272                               26.13                            442     26.40
  GA                549                               52.74                            816     48.75
  GG                220                               21.13                            416     24.85
  GG+GA             769                               73.87                            1,232   73.60
  GA+AA             821                               78.87                            1,258   75.15
  G allele          989                               47.50                            1,648   49.22

###### Overall and stratified analyses of *PD-1* rs10204525 T\>C, rs36084323 T\>C, rs7421861 A\>G and rs2227982 A\>G polymorphisms with esophagogastric junction adenocarcinoma

  Genotype           Overall (1,063 cases vs. 1,677 controls)                                          
  ------------------ ------------------------------------------ -------------- ----------------------- --------------
  rs36084323 T\>C                                                                                      
  additive model     0.96 (0.80--1.15)                          0.642          0.97 (0.81--1.17)       0.766
  homozygote model   0.81 (0.66--1.01)                          0.061          0.82 (0.66--1.02)       0.074
  Dominant model     0.97 (0.82--1.16)                          0.746          0.99 (0.83--1.18)       0.888
  Recessive model    0.86 (0.72--1.03)                          0.097          0.86 (0.71--1.03)       0.097
  rs10204525 T\>C                                                                                      
  additive model     0.91 (0.77--1.07)                          0.246          0.92 (0.78--1.08)       0.294
  homozygote model   1.14 (0.86--1.51)                          0.359          1.16 (0.87--1.54)       0.310
  Dominant model     0.99 (0.84--1.15)                          0.845          1.00 (0.85--1.16)       0.956
  Recessive model    1.22 (0.93--1.60)                          0.160          1.23 (0.94--1.62)       0.139
  rs7421861 A\>G                                                                                       
  additive model     **1.39 (1.17--1.64)**                      **\< 0.001**   **1.39 (1.18--1.65)**   **\< 0.001**
  homozygote model   1.34 (0.88--2.03)                          0.173          1.31 (0.86--1.98)       0.214
  Dominant model     **1.43 (1.21--1.68)**                      **\< 0.001**   **1.43 (1.21--1.68)**   **\<0.001**
  Recessive model    1.23 (0.81--1.86)                          0.327          1.20 (0.79--1.82)       0.394
  rs2227982 A\>G                                                                                       
  additive model     1.02 (0.85--1.22)                          0.845          1.04 (0.86--1.25)       0.690
  homozygote model   **0.80 (0.64--1.00)**                      **0.047**      0.81 (0.65--1.01)       0.057
  Dominant model     1.01 (0.85--1.21)                          0.874          1.03 (0.87--1.23)       0.716
  Recessive model    **0.81 (0.67--0.98)**                      **0.026**      **0.81 (0.67--0.97)**   **0.024**

^a^Adjusted for age, sex, smoking status and alcohol use in a logistic regression model.

The frequencies of *PD-1* rs7421861 AA, AG, and GG genotypes were 61.67%, 34.39% and 3.94% in 1,063 EGJA patients and 69.65%, 27.12%, and 3.23% in 1,677 controls, respectively. When compared with the frequency of *PD-1* rs7421861 AA genotype, there was difference in the frequency of *PD-1* rs7421861 AG genotype between the EGJA patients and the controls (crude OR = 1.39, 95% CI: 1.17--1.64, *P* \< 0.001). When compared with the frequency of *PD-1* rs7421861 AA genotype, there was also difference in the frequency of *PD-1* rs7421861 AG/GG genotype between the EGJA patients and the controls (crude OR = 1.43, 95% CI: 1.21--1.68, *P* \< 0.001). Adjustments for age, sex, smoking and drinking, the observed results were not essentially changed (AG vs. AA: adjusted OR, 1.39; 95% CI, 1.18--1.65; *P* \< 0.001; AG/GG vs. AA: adjusted OR, 1.43; 95% CI, 1.21--1.68; *P* \< 0.001; Table [4](#T4){ref-type="table"}).

The *PD-1* rs36084323 T\>C polymorphism conferred a borderline statistically decreased risk to EGJA in homozygote genetic model (crude OR = 0.81, 95% CI = 0.66--1.01, *P* = 0.061) and recessive genetic model (crude OR = 0.86, 95% CI = 0.72--1.03, *P* = 0.097). When adjusted for age, sex, smoking and drinking, a borderline statistically decreased risk of EGJA was also found in homozygote genetic model (crude OR = 0.82, 95% CI = 0.66--1.02, *P* = 0.074) and recessive genetic model (crude OR = 0.86, 95% CI = 0.71--1.03, *P* = 0.097). However, there was no difference in genotype distribution of *PD-1* rs10204525 T\>C polymorphism among EGJA patients and the controls (Table [4](#T4){ref-type="table"}).

We used the Power and Sample Size Calculator (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>) to calculate the power value (α = 0.05) \[[@R22]\]. For *PD-1* rs7421861 A\>G, the power value was 0.967 in the additive model and 0.990 in the dominant model. For *PD-1* rs2227982 A\>G, the power value was 0.675 in the homozygote model and 0.607 in the recessive model.

Association of PD-1 rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms with EGJA in different stratification groups {#s2_3}
--------------------------------------------------------------------------------------------------------------------------------------------------

Table [5](#T5){ref-type="table"} summarizes the genotype frequencies of *PD-1* rs10204525 T\>C polymorphism in the stratified analysis by gender, age, alcohol consumption and smoking status. There was no significant difference in genotype distribution of *PD-1* rs10204525 T\>C polymorphism among EGJA patients and the controls in any subgroup.

###### Stratified analyses between PD-1 rs10204525 T\>C polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              PD-1 rs10204525 T\>C (case/control) a   Adjusted OR b (95% CI); *P*                                                                                     
  --------------------- --------------------------------------- ----------------------------- -------- ------ --------------------- --------------------- --------------------- ---------------------
  Sex                                                                                                                                                                           

  Male                  384/621                                 289/476                       71/94    1.00   0.96 (0.79--1.17);\   1.20 (0.86--1.67);\   1.04 (0.86--1.25);\   1.24(0.90--1.72);\
                                                                                                              *P*: 0.704            *P*: 0.294            *P*: 0.700            *P*: 0.194

  Female                160/249                                 108/196                       27/38    1.00   0.79(0.58--1.08);\    1.08 (0.63--1.85);\   0.89(0.66--1.19);\    1.23 (0.73--2.08);\
                                                                                                              *P*: 0.140            *P*: 0.776            *P*: 0.422            *P*: 0.433

  Age                                                                                                                                                                           

  \<64                  245/442                                 187/310                       50/71    1.00   1.04 (0.82--1.33);\   1.26 (0.85--1.87);\   1.13(0.90--1.42);\    1.27 (0.86--1.86);\
                                                                                                              *P*: 0.725            *P*: 0.260            *P*: 0.283            *P*: 0.226

  ≥64                   299/428                                 210/362                       48/61    1.00   0.80 (0.64--1.01);\   1.10 (0.73--1.66);\   0.88 (0.71--1.09);\   1.24 (0.83--1.84);\
                                                                                                              *P*: 0.055            *P*: 0.640            *P*: 0.237            *P*: 0.291

  Smoking status                                                                                                                                                                

  Never                 385/679                                 300/534                       68/108   1.00   0.94(0.78--1.13);\    1.08(0.78--1.50);\    1.01 (0.84--1.21);\   1.14 (0.83--1.57);\
                                                                                                              *P*: 0.505            *P*: 0.644            *P*: 0.926            *P*: 0.419

  Ever                  159/191                                 97/138                        30/24    1.00   0.84 (0.60--1.18);\   1.60 (0.89--2.88);\   0.97 (0.71--1.33);\   1.74 (0.98--3.08);\
                                                                                                              *P*: 0.321            *P*: 0.115            *P*: 0.849            *P*: 0.058

  Alcohol consumption                                                                                                                                                           

  Never                 464/774                                 339/610                       83/121   1.00   0.89(0.74--1.05);\    1.11 (0.82--1.50);\   0.96 (0.82--1.14);\   1.20(0.89--1.61);\
                                                                                                              *P*: 0.171            *P*: 0.508            *P*: 0.660            *P*: 0.230

  Ever                  80/96                                   58/62                         15/11    1.00   1.11 (0.68--1.79);\   2.22(0.91--5.43);\    1.26 (0.80--1.99);\   2.14 (0.89--5.10);\
                                                                                                              *P*: 0.680            *P*: 0.080            *P*: 0.328            *P*: 0.088
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^The genotyping was successful in 1063 (97.74%) EGJA cases, and 1677 (99.82%) controls for *PD-1* rs10204525 T\>C;

^b^Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

The genotype frequencies of *PD-1* rs36084323 T\>C polymorphism in the stratified analysis by gender, age, alcohol consumption and smoking status are summarized in Table [6](#T6){ref-type="table"}. In never smoking group, after adjustment for gender, age, alcohol consumption and smoking status by logistic regression analysis, the *PD-1* rs36084323 CC genotype was associated with a significantly decreased risk of EGJA compared with the TC/TT genotype \[CC vs. TC/TT: adjusted OR = 0.80, 95% CI 0.65--0.99, *P* = 0.043 (Table [6](#T6){ref-type="table"})\]. In never drink group, after logistic regression analysis, the CC genotype of *PD-1* rs36084323 T\>C polymorphism was also associated with a significantly decreased risk of EGJA compared with the TT genotype \[CC vs. TT: adjusted OR = 0.78, 95% CI 0.62--0.99, *P* = 0.037 (Table [6](#T6){ref-type="table"})\].

###### Stratified analyses between PD-1 rs36084323 T\>C polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              PD-1 rs36084323 T\>C (case/control)^a^   Adjusted OR b (95% CI); *P*                                                                                      
  --------------------- ---------------------------------------- ----------------------------- --------- ------ --------------------- --------------------- --------------------- ---------------------
  Sex                                                                                                                                                                             

  Male                  198/316                                  368/561                       180/314   1.00   1.01 (0.81--1.26);\   0.88 (0.68--1.14);\   1.02 (0.83--1.26);\   0.89(0.72--1.11);\
                                                                                                                *P*: 0.918            *P*: 0.331            *P*: 0.840            *P*: 0.296

  Female                84/128                                   153/239                       58/116    1.00   0.88(0.63--1.24);\    0.69 (0.45--1.04);\   0.91(0.65--1.26);\    0.77 (0.54--1.11);\
                                                                                                                *P*: 0.462            *P*: 0.077            *P*: 0.561            *P*: 0.160

  Age                                                                                                                                                                             

  \<64                  130/215                                  240/411                       112/197   1.00   0.90 (0.69--1.17);\   0.87 (0.63--1.19);\   0.96(0.74--1.24);\    0.96 (0.74--1.26);\
                                                                                                                *P*: 0.415            *P*: 0.382            *P*: 0.768            *P*: 0.769

  ≥64                   152/229                                  281/389                       126/233   1.00   1.03 (0.80--1.33);\   0.79 (0.58--1.05);\   0.99 (0.78--1.27);\   0.78 (0.61--1.00);\
                                                                                                                *P*: 0.833            *P*: 0.098            *P*: 0.962            *P*: 0.053

  Smoking status                                                                                                                                                                  

  Never                 195/352                                  395/631                       164/338   1.00   1.04(0.84--1.28);\    0.80(0.62--1.03);\    1.04 (0.85--1.27);\   0.80 (0.65--0.99);\
                                                                                                                *P*: 0.750            *P*: 0.078            *P*: 0.715            P: 0.043

  Ever                  87/92                                    126/169                       74/92     1.00   0.80(0.55--1.17);\    0.90 (0.58--1.38);\   0.85 (0.60--1.22);\   1.04 (0.72--1.49);\
                                                                                                                *P*: 0.244            *P*: 0.615            *P*: 0.379            *P*: 0.834

  Alcohol consumption                                                                                                                                                             

  Never                 235/389                                  450/722                       202/394   1.00   0.95(0.78--1.16);\    0.78 (0.62--0.99);\   0.97 (0.80--1.17);\   0.83(0.68--1.01);\
                                                                                                                *P*: 0.638            P: 0.037              *P*: 0.739            *P*: 0.058

  Ever                  47/55                                    71/78                         36/36     1.00   1.10 (0.65--1.86);\   1.18(0.63--2.21);\    1.13(0.69--1.84);\    1.11 (0.65--1.92);\
                                                                                                                *P*: 0.712            *P*: 0.598            *P*: 0.630            *P*: 0.697
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *PD-1* rs36084323 T\>C;

^b^Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

In the stratified analysis by gender, age, alcohol consumption and smoking status, the genotype frequencies of *PD-*1 rs7421861 A\>G polymorphism are summarized in Table [7](#T7){ref-type="table"}. After adjustment by logistic regression analysis, we found that *PD-*1 rs7421861 A\>G polymorphism was associated with a significantly increased risk of EGJA in some subgroups \[male group: AG vs. AA: adjusted OR = 1.40, 95% CI 1.15--1.70, *P* = 0.001 and AG/GG vs. AA: adjusted OR = 1.41, 95% CI 1.16--1.71, *P* = 0.001; female group: AG/GG vs. AA: adjusted OR = 1.46, 95% CI 1.07--2.00, *P* = 0.017; \<64 years subgroup: AG vs. AA: adjusted OR = 1.62, 95% CI 1.27--2.08, *P* \< 0.001; GG vs. AA: adjusted OR = 2.07, 95% CI 1.12--3.83, *P* = 0.021 and AG/GG vs. AA: adjusted OR = 1.73, 95% CI 1.36--2.20, *P* \< 0.001; never smoking group: AG vs. AA: adjusted OR = 1.42, 95% CI 1.17--1.73, *P* \< 0.001 and AG/GG vs. AA: adjusted OR = 1.45, 95% CI 1.20--1.75, *P* \< 0.001 and never drinking group: AG vs. AA: adjusted OR = 1.42, 95% CI 1.19--1.70, *P* \< 0.001 and AG/GG vs. AA: adjusted OR = 1.46, 95% CI 1.22--1.73, *P* \< 0.001 (Table [7](#T7){ref-type="table"})\].

###### Stratified analyses between *PD-1* rs7421861 A\>G polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  Variable              PD-1 rs7421861 A\>G (case/control)^a^   Adjusted OR b (95% CI); *P*                                                                                                                    
  --------------------- --------------------------------------- ----------------------------- ------- ------ -------------------------------- ------------------------------- -------------------------------- -------------------------------
  Sex                                                                                                                                                                                                          
  Male                  455/819                                 262/331                       29/41   1.00   1.40 (1.15--1.70); P: 0.001      1.20 (0.74--1.97); *P*: 0.462   1.41 (1.16--1.71); P: 0.001      1.10 (0.67--1.79); *P*: 0.712
  Female                187/347                                 96/123                        12/13   1.00   1.37 (0.99--1.89); *P*: 0.058    1.65 (0.73--3.69); *P*: 0.228   1.46 (1.07--2.00); P: 0.017      1.55(0.69--3.46); *P*: 0.286
  Age                                                                                                                                                                                                          
  \<64                  286/590                                 173/212                       23/21   1.00   1.62 (1.27--2.08); P: \< 0.001   2.07 (1.12--3.83); P: 0.021     1.73 (1.36--2.20); P: \< 0.001   1.82 (0.99--3.35); *P*: 0.054
  ≥64                   356/576                                 185/242                       18/33   1.00   1.21 (0.96--1.53); *P*: 0.108    0.87 (0.48--1.56); *P*: 0.633   1.20 (0.96--1.50); *P*: 0.113    0.83 (0.46--1.49); *P*: 0.531
  Smoking status                                                                                                                                                                                               
  Never                 465/925                                 263/353                       26/43   1.00   1.42 (1.17--1.73); P: \< 0.001   1.16 (0.70--1.92); *P*: 0.558   1.45 (1.20--1.75); P: \< 0.001   1.07 (0.65--1.75); *P*: 0.804
  Ever                  177/241                                 95/101                        15/11   1.00   1.29 (0.91--1.82); *P*: 0.149    1.85 (0.82--4.17); *P*: 0.139   1.36 (0.98--1.90); *P*: 0.068    1.72 (0.77--3.85); *P*: 0.188
  Alcohol consumption                                                                                                                                                                                          
  Never                 544/1050                                311/408                       32/47   1.00   1.42 (1.19--1.70); P: \< 0.001   1.26 (0.80--2.00); *P*: 0.326   1.46 (1.22--1.73); P: \< 0.001   1.15 (0.73--1.82); *P*: 0.541
  Ever                  98/116                                  47/46                         9/7     1.00   1.14 (0.69--1.89); *P*: 0.609    1.73 (0.59--5.09); *P*: 0.322   1.21 (0.75--1.95); *P*: 0.441    1.66 (0.57--4.83); *P*: 0.356

^a^ The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *PD-1* rs7421861 A\>G;

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

In the stratified analysis by gender, age, alcohol consumption and smoking status, the genotype frequencies of *PD-1* rs2227982 A\>G polymorphism are summarized in Table [8](#T8){ref-type="table"}. After adjustment by logistic regression analysis, the *PD-1* rs2227982 GG genotype was associated with a decreased risk of EGJA compared with the AG/AA genotype in three groups \[≥ 64 years subgroup: GG vs. AG/AA: adjusted OR = 0.72, 95% CI 0.56--0.93, *P* = 0.011; never smoking group: GG vs. AG/AA: adjusted OR = 0.74, 95% CI 0.60--0.92, *P* = 0.008 and never drinking group: GG vs. AG/AA: adjusted OR = 0.76, 95% CI 0.62--0.93, *P* = 0.008 (Table [8](#T8){ref-type="table"})\]. Additionally, compared with the *PD-1* rs2227982 AA genotype, the *PD-1* rs2227982 GG genotypes were also associated with a significantly decreased risk of EGJA in never drink group \[GG vs. AA: adjusted OR = 0.76, 95% CI 0.60--0.97, *P* = 0.024 (Table [8](#T8){ref-type="table"})\].

###### Stratified analyses between *PD-1* rs2227982 A\>G polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  Variable              PD-1 rs2227982 A\>G (case/control) a   Adjusted OR b (95% CI); *P*                                                                                                                      
  --------------------- -------------------------------------- ----------------------------- --------- ------ ------------------------------- --------------------------------- ------------------------------- ---------------------------------
  Sex                                                                                                                                                                                                           
  Male                  188/315                                393/572                       165/304   1.00   1.12(0.89--1.39); *P*: 0.333    0.87 (0.67--1.14); *P*: 0.310     1.10 (0.89--1.35); *P*: 0.399   0.83 (0.67--1.03); *P*: 0.093
  Female                84/127                                 156/244                       55/112    1.00   0.87 (0.62--1.23); *P*: 0.433   0.66 (0.43--1.01); *P*: 0.057     0.90 (0.65--1.24); *P*: 0.513   0.75 (0.52--1.08); *P*: 0.124
  Age                                                                                                                                                                                                           
  \<64                  126/212                                253/426                       103/185   1.00   0.93 (0.71--1.22); *P*: 0.597   0.87 (0.63--1.20); *P*: 0.383     0.99 (0.77--1.29); *P*: 0.948   0.93 (0.71--1.23); *P*: 0.625
  ≥64                   146/230                                296/390                       117/231   1.00   1.13(0.87--1.45); *P*: 0.359    0.76 (0.56--1.03); *P*: 0.074     1.06 (0.83--1.35); *P*: 0.666   **0.72 (0.56--0.93); P: 0.011**
  Smoking status                                                                                                                                                                                                
  Never                 188/351                                415/638                       151/332   1.00   1.11 (0.90--1.37); *P*: 0.339   0.77 (0.60--1.00); *P*: 0.051     1.09 (0.89--1.34); *P*: 0.422   **0.74(0.60--0.92); P: 0.008**
  Ever                  84/91                                  134/178                       69/84     1.00   0.84 (0.58--1.22); *P*: 0.365   0.94 (0.61--1.46); *P*: 0.788     0.90 (0.63--1.28); *P*: 0.542   1.06 (0.73--1.54); *P*: 0.752
  Alcohol consumption                                                                                                                                                                                           
  Never                 224/387                                481/739                       182/379   1.00   1.04 (0.85--1.26); *P*: 0.714   **0.76 (0.60--0.97); P: 0.024**   1.03 (0.85--1.24); *P*: 0.783   **0.76 (0.62--0.93); P: 0.008**
  Ever                  48/55                                  68/77                         38/37     1.00   0.99 (0.59--1.67); *P*: 0.961   1.30 (0.70--2.41); *P*: 0.410     1.08 (0.67--1.76); *P*: 0.753   1.30 (0.76--2.24); *P*: 0.339

^a^The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *PD-1* rs2227982 A\>G;

^b^Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

SNP haplotypes {#s2_4}
--------------

Using SHESIS software (<http://analysis.bio-x.cn/myAnalysis.php>) \[[@R23]\], we constructed six haplotypes (Table [9](#T9){ref-type="table"}). We found that TGCA haplotypes with the order of *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms in gene position significantly decreased the risk of EGJA (OR = 0.83, 95% CI = 0.71--0.96; *P* = 0.015). However, TGCG and other haplotypes with the same order of *PD-1* SNPs in gene position significantly increased the risk of EGJA (OR = 22.19, 95% CI = 5.27--93.56; *P* \< 0.001 and OR = 2.50, 95% CI = 1.73--3.60; *P* \< 0.001).

###### PD-1 haplotype frequencies (%) in cases and controls and risk of esophagogastric junction adenocarcinom

  Haplotypes                                           Case (n=2,126)   Control (n=3,354)   Crude OR (95% CI)   *P*                              
  ---------------------------------------------------- ---------------- ------------------- ------------------- ------- ------------------------ -------------
  T~rs10204525~A~rs2227982~T~rs36084323~A~rs74218~61   1000             49.24               1644                49.07   1.00                     
  C~rs10204525~G~rs2227982~C~rs36084323~G~rs7421861~   354              17.43               544                 16.24   1.07(0.92--1.25)         0.394
  T~rs10204525~G~rs2227982~C~rs36084323~A~rs7421861~   347              17.09               688                 20.54   **0.83(0.71--0.96)**     **0.015**
  C~rs10204525~G~rs2227982~C~rs36084323~A~rs7421861~   198              9.75                374                 11.16   0.87(0.72--1.05)         0.150
  T~rs10204525~A~rs2227982~C~rs36084323~A~rs7421861~   29               1.43                48                  1.43    0.99(0.62--1.59)         0.977
  T~rs10204525~G~rs2227982~C~rs36084323~G~rs7421861~   27               1.33                2                   0.06    **22.19(5.27--93.56)**   **\<0.001**
  Others                                               76               3.74                50                  1.49    **2.50(1.73--3.60)**     **\<0.001**

DISCUSSION {#s3}
==========

EGJA is considered as a separated carcinoma entirety of upper digestive tract malignancies \[[@R24]\]. Although the incidence of GC is declining, the incidence of EGJA rapidly increases in both western (e.g. North America and Europe) and eastern Asian countries \[[@R2]--[@R4], [@R25]\]. Thus, EGJA is one of the most prevalent malignancies worldwide. The etiology of EGJA is very complicated. Accumulating evidences demonstrated that SNPs in some immune response genes might be associated with risk of cancer \[[@R6], [@R26]--[@R28]\]. In consideration of the vital role of PD-1 in tumor immunology, we chose *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms to examine their potential roles in EGJA. In the present study, we found that *PD-1* rs2227982 A\>G and rs36084323 T\>C polymorphisms might decrease the risk of EGJA. However, *PD-1* rs7421861 A\>G might be a risk factor for EGJA. In addition, we found T~rs10204525~G~rs2227982~C~rs36084323~A~rs7421861~ haplotypes significantly decreased the risk of EGJA. On the contrary, T~rs10204525~G~rs2227982~C~rs36084323~G~rs7421861~ and other haplotypes increased the risk of EGJA.

*PD-1* rs7421861 A\>G polymorphism locates on intron 1, where a lot of regulatory components and splicing control elements may interact with it \[[@R29]\]. Some epidemiological studies focused on the effect of *PD-1* rs7421861 A\>G locus on the development of multiple cancers; however, the results remained inconsistent. Several case-control reported that *PD-1* rs7421861 A\>G polymorphism was not associated with cancer risk \[[@R19], [@R27], [@R28], [@R30]\]. However, Ge *et al*. found *PD-1* rs7421861 A\>G polymorphism might increase the risk of overall colorectal cancer \[[@R31]\]. Recently, a meta-analysis indicated that *PD-1* rs7421861 A\>G was correlated with a borderline statistically increased risk of overall cancer \[[@R32]\]. In the present study, we found *PD-1* rs7421861 A\>G polymorphism might be associated with the susceptibility of EGJA, which was similar to the findings of the previous studies \[[@R31], [@R32]\]. This study did not examine the potential effect of this polymorphism on regulating the expression of PD-1 in EGJA patient blood samples. However, in the future, we will conduct a further study to assess whether *PD-1* rs7421861 A\>G polymorphism is associated with the inhibited activation of T cells in EGJA patients, which may impede the surveillance mechanism of immune system.

*PD-1* rs2227982 A\>G polymorphism, a SNP in Exon 5, encodes a Val to Ala substitution in the extra-cellular domain of PD-1 receptor during protein synthesis, which influences the sequence, and may alter the function of PD-1 protein. In this study, we found that *PD-1* rs2227982 A\>G polymorphism was associated with the decreased risk of EGJA risk. Ren *et al*. reported that *PD-1* rs2227982 A\>G polymorphism was associated with the development of breast cancer \[[@R19]\]. In addition, several studies reported there was no significant association between *PD-1* rs2227982 A\>G polymorphism and cancer (e.g. esophageal squamous cell carcinoma, colorectal cancer, breast cancer and non-small cell lung cancer) \[[@R27], [@R28], [@R30], [@R31]\]. A recent meta-analysis suggested that *PD-1* rs2227982 A\>G polymorphism might be not associated with the risk of overall cancer. However, we found that only five case-control studies with relatively small sample sizes were included in this pooled analysis. The current evidence of the relationship might be very limited. Therefore, whether the Val to Ala substitution in the extra-cellular domain of PD-1 recepter does alter biological activity of PD-1 protein is needed to be further assessed.

Previous report showed that *PD-1* rs36084323 CC was associated with a significantly decreased risk of breast cancer compared with the TT genotype \[[@R30]\]. In the present study, we found a borderline statistically decreased risk to EGJA in homozygote genetic model and recessive genetic model. In the stratified analysis by gender, age, alcohol consumption and smoking status, the decreased risk was observed in never smoking group and in never drinking group. To the best of our knowledge, variants in the promoter region of functional gene may influence an initial binding of transcription factors with sequence motifs, and further alter gene expression \[[@R33], [@R34]\]. Accordingly, as a variant in promoter region of PD-1 gene, *PD-1* rs36084323 CC genotype may also affect the activation of transcription, and then regulate the expression of PD-1 gene and increase the risk of EGJA.

In this study, we constructed haplotypes to explore the potential inherited patterns of haplotype. We found that *PD-1* T~rs10204525~G~rs2227982~C~36084323~A~rs7421861~ haplotype significantly decreased the risk of EGJA. However, T~rs10204525~G~rs2227982~C~36084323~G~rs7421861~ haplotype in *PD-1* gene might significantly increase the risk of EGJA. We first studied the relationship of haplotypes in *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms with EGJA susceptibility. Compared *PD-1* T~rs10204525~G~rs2227982~C~36084323~A~rs7421861~ with T~rs10204525~G~rs2227982~C~36084323~G~rs7421861~ haplotype, we also found that A→G variation in *PD-1* rs7421861 locus might significantly inverse the risk of haplotype to EGJA.

In addition, some limitations in this case-control study should be acknowledged. All participants were enrolled in three hospitals from Eastern Chinese Han population. Although the genotype distributions of *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms in controls were consistent with HWE and the MAF in the selected controls was very close to the data of Chinese (Table [2](#T2){ref-type="table"}), the non-cancer controls might not well-represent the whole Chinese population. As well, only four important SNPs (MAF ≥ 0.05) in *PD-1* gene were selected, which might not be enough to determine the total genetic susceptibility in *PD-1* gene. Future, a fine-mapping study with larger sample sizes, multiple centers and detailed risk factors is need to confirm these primary findings.

In summary, our study highlights rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms and haplotypes in *PD-1* gene, especially within the intron region, may be associated with the risk of EGJA in Eastern Chinese Han population. Our primary findings suggest that *PD-1* genetic variation may be beneficial for the exploration of Eastern Chinese subjects genetically susceptible to EGJA.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

A total of 2,740 participants were recruited in this case-control study. Among them, 280 EGJA patients were enrolled from the Affiliated Union Hospital of Fujian Medical University and Fujian Medical University Cancer Hospital from January 2014 to May 2016. In addition, 783 EGJA patients were recruited from the Affiliated People\'s Hospital of Jiangsu University from January 2008 to November 2016. All cases with histologically confirmed EGJA were enrolled in the present study. EGJA patients who had a history of another malignancy or received prior chemoradiotherapy were excluded. At the same time, 1,677 subjects who underwent health check in these hospitals were recruited as non-cancer controls. Controls were matched with EGJA cases in terms of gender and age. All participants were unrelated Eastern Chinese Han population. Each participant signed the written informed consent. The study was approved by the Review Boards of Jiangsu University (Zhenjiang, China) and Fujian Medical University (Fuzhou, China), in accordance with the Declaration of Helsinki. Two experienced doctors interviewed each individual and collected the relevant risk factors and demographic variables. The corresponding data are summarized in Table [1](#T1){ref-type="table"}. Each study participant provided an ethylenediamine tetraacetic acid (EDTA)-anticoagulated intravenous blood sample after an overnight fast. The approved guidelines were used as experimental protocol.

Selection of SNPs {#s4_2}
-----------------

The tagging polymorphisms among the gene region of *PD-1* (upstream and downstream of gene extending 5 Kb, respectively) were collected from the CHB population via an internet the HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/index.html.en>) and were conducted with Haploview 4.2 software with the criterion of pairwise linkage disequilibrium (LD) *r*^2^ threshold of 0.8 between polymorphisms (with a minimum LD of *r*^2^ \> 0.8) \[[@R35]\]. Finally, SNPs with a HWE *P* ≥ 0.05, MAF ≥ 0.05 and call rate ≥ 95 % in the CHB population were included \[[@R36]\]. *PD-1* rs36084323 T\>C polymorphism locates on the promoter of *PD-1* gene, which region may influence the transcription of *PD-1*. Thus, in this study, we also included this important SNP. The primary information of PD-1 functional SNPs is summarized in Table [2](#T2){ref-type="table"}.

DNA extraction and genotyping {#s4_3}
-----------------------------

Peripheral blood sample was collected and stored at −20°C. Using the Promega Genomic DNA Purification Kit (Promega, Madison, USA), the genomic DNA was carefully extracted from lymphocytes. The obtained genomic DNA was frozen at −80°C. SNPscan^TM^ genotyping assay (Gnensky Biotechologies Inc., Shanghai, China) was used to analyze the genotyping of *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms. For quality control, 110 DNA samples (4%) were randomly selected. The genotypes of *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms were reanalyzed by different laboratory technicians. The reproducibility was 100%. The success rate of *PD-1* genotyping is shown in Table [2](#T2){ref-type="table"}.

Statistical analysis {#s4_4}
--------------------

Age was expressed as the mean ± standard deviation (SD). And we used Student\'s *t*-test to calculate the differences for continuous variables between EGJA patients and controls. An internet-based calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) was used to determine the deviation of genotype frequencies from HWE. Chi-square test (*χ*^2^) was conducted to compare the categorical variables (e.g. age, sex, smoking status, and drinking) and the genotype distributions between EGJA patients and non-cancer controls. Multivariate logistic regression was used to obtain the crude/adjusted odds ratios (OR) and their 95 % confidence intervals (CI) for the relationship of *PD-1* rs10204525 T\>C, rs2227982 A\>G, rs36084323 T\>C and rs7421861 A\>G polymorphisms with EGJA risk. The SAS software (Version 9.4; SAS Institute Inc., Cary, NC, USA) was used to analyze all data. SHESIS online software \[(<http://analysis.bio-x.cn/myAnalysis.php>), Bio-X Inc., Shanghai, China\] was harnessed to construct the haplotypes of *PD-1* gene \[[@R23]\]. The criterion of statistical significance was defined as *P* \< 0.05 (two-tailed). We performed the Power and Sample Size Calculator (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>) to assess the power value of the study (α = 0.05) \[[@R22]\].
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